Skip to content

Ultrasound to Assess Sarcopenia in Prader Willi Syndrome

Usefulness of Ultrasound to Assess Sarcopenia in Individuals With Prader Willi Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06448871
Acronym
PWS
Enrollment
49
Registered
2024-06-07
Start date
2022-10-17
Completion date
2024-06-30
Last updated
2024-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prader-Willi Syndrome, Sarcopenia, Metabolic Syndrome

Keywords

Prader-Willi Syndrome, Sarcopenia, Ultrasound, skeletal muscle, body composition

Brief summary

The aim of the study is to examine the clinical applicability of ultrasound as a diagnostic tool for sarcopenia in individuals with PWS by investigating the association between ultrasound-derived measurements, DXA-derived measurements, and sarcopenia-related outcomes.

Detailed description

Sarcopenia is an age-related loss of muscle mass plus low muscle strength, and/or low physical performance, that may affect over 25% of individuals over the age of 60, resulting in an increased likelihood of developing disability. Abnormal body composition with an increased in body fat mass and a decreased in skeletal muscle mass were noted in individuals with Prader Willi syndrome (PWS), thought to be related to hormonal deficiencies due to hypothalamic dysfunction, presenting as a unique congenital model of sarcopenia. Muscle mass can be measured by dual-energy X-ray absorptiometry (DXA) scan device, but it is expensive, increased radiation exposure, and not easily accessible in all clinical practice. Ultrasound (USD) is a non-invasive, without ionising radiation, low-cost, and easily accessible tool for the assessment of soft tissue. There were increasing evidence for the use of USD in the measurement of muscle thickness (MT), cross-sectional area (CSA) and pennate anle (PA) of different muscle groups in different populations. However, the use of USD as a routine diagnostic tool in individuals with PWS has not been reported yet. The aim of the study is to examine the clinical applicability of ultrasound as a diagnostic tool for sarcopenia in individuals with PWS by investigating the association between ultrasound-derived measurements, DXA-derived measurements, and sarcopenia-related outcomes.

Interventions

DIAGNOSTIC_TESTUltrasound assessment of the right lower extremity muscles

Rectus femoris cross sectional area (RFCSA), RF muscle thickness, vastus lateralis (VL) muscle thickness, Gastrocnemius medialis (GM) muscle thickness, VL pennation angle (PA), and GM PA.

skeletal muscle mass (SM), appendicular skeletal muscle mass index (ASMI), total lean body mass (LBM), total fat mass (BF), percentage fat mass, and fat mass index (FMI).

Sponsors

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
7 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Genetically diagnosed individuals with PWS who can cooperate with the examinations

Exclusion criteria

* Individuals with PWS who have arthritis, fractures, or severe musculoskeletal deformities that could interfere with the examinations. * Individuals with PWS who have severe cognitive impairment and are unable to read or sign the written consent.

Design outcomes

Primary

MeasureTime frameDescription
DXA: percentage fat mass1 dayAdipose index of percentage fat mass using Hologic QDR-4500A, Hologic, Inc., Waltham, MA, USA.
DXA: skeletal muscle (SM)1 dayLean index of skeletal muscle (SM) with Hologic QDR-4500A, Hologic, Inc., Waltham, MA, USA
DXA: appendicular skeletal muscle mass index (ASMI)1 dayLean index of appendicular skeletal muscle mass index (ASMI) with Hologic QDR-4500A, Hologic, Inc., Waltham, MA, USA
DXA: fat mass index (FMI)1 dayAdipose index of fat mass index using Hologic QDR-4500A, Hologic, Inc., Waltham, MA, USA.
DXA: body fat mass (BFM)1 dayAdipose index of body fat mass (BFM) using Hologic QDR-4500A, Hologic, Inc., Waltham, MA, USA.
Muscle thickness ultrasound1 dayUltrasound scanning of the muscle thickness of rectus femoris (RF), vastus lateralis (VL), and gastrocnemius medialis (GM) using B-mode ultrasonography (LOGIQ S8, GE Healthcare, USA) and a 7-15 MHz linear array transducer.
Cross-sectional area ultrasound1 dayUltrasound scanning of the cross sectional area of rectus femoris (RF) using B-mode ultrasonography (LOGIQ S8, GE Healthcare, USA) and a 7-15 MHz linear array transducer.
Pennation angle ultrasound1 dayUltrasound scanning of the pennation angles of vastus lateralis (VL) and gastrocnemius medialis (GM) using B-mode ultrasonography (LOGIQ S8, GE Healthcare, USA) and a 7-15 MHz linear array transducer.
DXA: total lean body mass1 dayLean index of total lean body mass (LBM) with Hologic QDR-4500A, Hologic, Inc., Waltham, MA, USA

Secondary

MeasureTime frameDescription
Physical performance test: SPPB1 dayThe short physical performance battery (SPPB) will be used, which measures balance, walking speed, strength, and endurance in the lower limbs, and is scored from zero to 12 (worst to best score).
Physical performance test: gait speed1 dayIn the gait speed test participants walk over a 4-meter distance at their normal pace.
Physical performance test: five-time chair stand test1 dayIn the 5-time chair stand test participants perform five sit-to-stand movements as quickly as possible
Handgrip and lateral pinch strength1 dayGrip strength and lateral pinch will be assessed bilaterally using an isometric Baseline hydraulic hand dynamometer and pinch gauge.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026